Uveal Melanoma clinical trials

Explore recruiting uveal melanoma clinical trials.

Recruiting uveal melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Uveal Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma

Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial)

Germany, Spain, France, Poland, Italy, Belgium +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

AMUM trial -Adjuvant Melatonin for Uveal Melanoma: A randomized open Phase III Study

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

(Neo)adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma

Italy, France, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Uveal Melanoma trials by city

Uveal Melanoma in Toronto Uveal Melanoma in Vancouver Uveal Melanoma in Montreal Uveal Melanoma in Calgary Uveal Melanoma in Edmonton Uveal Melanoma in Ottawa Uveal Melanoma in Winnipeg Uveal Melanoma in Quebec City Uveal Melanoma in Hamilton Uveal Melanoma in Kitchener Uveal Melanoma in London Uveal Melanoma in Halifax Uveal Melanoma in New York Uveal Melanoma in Los Angeles Uveal Melanoma in Chicago Uveal Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease